For example, Pedersen and colleagues generated bispecific nanobodies binding properdin and the validated cancer antigen EGFR, and showed that these bispecific molecules were able to activate complement on EGFR-expressing cancer cells (29). The gene discussed is EGFR; the disease is cancer.